Diagnosis of a malignant adrenal mass

the role of urinary steroid metabolite profiling

Irina Bancos, Wiebke Arlt

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Adrenal masses are highly prevalent, found in 5% of the population. Differentiation of benign adrenocortical adenoma from adrenocortical carcinoma is currently hampered by the poor specificity and limited evidence base of imaging tests. This review summarizes the results of studies published to date on urine steroid metabolite profiling for distinguishing benign from malignant adrenal masses. RECENT FINDINGS: Three studies have described cohorts of at least 100 patients with adrenal tumors showing significant differences between urinary steroid metabolite excretions according to the nature of the underlying lesion, suggesting significant value of steroid metabolite profiling as a highly accurate diagnostic test. SUMMARY: Steroid profiling is emerging as a powerful novel diagnostic tool with a significant potential for improving the management for patients with adrenal tumors. Although the current studies use gas chromatography–mass spectrometry for proof of concept, widespread use of the method in routine clinical care will depend on transferring the approach to high-throughput tandem mass spectrometry platforms. The use of computational data analysis in conjunction with urine steroid metabolite profiling, that is, steroid metabolomics, adds accuracy and precision.

Original languageEnglish (US)
JournalCurrent Opinion in Endocrinology, Diabetes and Obesity
DOIs
StateAccepted/In press - Feb 23 2017

Fingerprint

Steroids
Glandular and Epithelial Neoplasms
Urine
Adrenocortical Adenoma
Adrenocortical Carcinoma
Metabolomics
Tandem Mass Spectrometry
Routine Diagnostic Tests
Spectrum Analysis
Gases
Population

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Nutrition and Dietetics

Cite this

Diagnosis of a malignant adrenal mass : the role of urinary steroid metabolite profiling. / Bancos, Irina; Arlt, Wiebke.

In: Current Opinion in Endocrinology, Diabetes and Obesity, 23.02.2017.

Research output: Contribution to journalArticle

@article{52ccb85234f84ac08177cea52c1c8560,
title = "Diagnosis of a malignant adrenal mass: the role of urinary steroid metabolite profiling",
abstract = "PURPOSE OF REVIEW: Adrenal masses are highly prevalent, found in 5{\%} of the population. Differentiation of benign adrenocortical adenoma from adrenocortical carcinoma is currently hampered by the poor specificity and limited evidence base of imaging tests. This review summarizes the results of studies published to date on urine steroid metabolite profiling for distinguishing benign from malignant adrenal masses. RECENT FINDINGS: Three studies have described cohorts of at least 100 patients with adrenal tumors showing significant differences between urinary steroid metabolite excretions according to the nature of the underlying lesion, suggesting significant value of steroid metabolite profiling as a highly accurate diagnostic test. SUMMARY: Steroid profiling is emerging as a powerful novel diagnostic tool with a significant potential for improving the management for patients with adrenal tumors. Although the current studies use gas chromatography–mass spectrometry for proof of concept, widespread use of the method in routine clinical care will depend on transferring the approach to high-throughput tandem mass spectrometry platforms. The use of computational data analysis in conjunction with urine steroid metabolite profiling, that is, steroid metabolomics, adds accuracy and precision.",
author = "Irina Bancos and Wiebke Arlt",
year = "2017",
month = "2",
day = "23",
doi = "10.1097/MED.0000000000000333",
language = "English (US)",
journal = "Current Opinion in Endocrinology, Diabetes and Obesity",
issn = "1752-296X",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Diagnosis of a malignant adrenal mass

T2 - the role of urinary steroid metabolite profiling

AU - Bancos, Irina

AU - Arlt, Wiebke

PY - 2017/2/23

Y1 - 2017/2/23

N2 - PURPOSE OF REVIEW: Adrenal masses are highly prevalent, found in 5% of the population. Differentiation of benign adrenocortical adenoma from adrenocortical carcinoma is currently hampered by the poor specificity and limited evidence base of imaging tests. This review summarizes the results of studies published to date on urine steroid metabolite profiling for distinguishing benign from malignant adrenal masses. RECENT FINDINGS: Three studies have described cohorts of at least 100 patients with adrenal tumors showing significant differences between urinary steroid metabolite excretions according to the nature of the underlying lesion, suggesting significant value of steroid metabolite profiling as a highly accurate diagnostic test. SUMMARY: Steroid profiling is emerging as a powerful novel diagnostic tool with a significant potential for improving the management for patients with adrenal tumors. Although the current studies use gas chromatography–mass spectrometry for proof of concept, widespread use of the method in routine clinical care will depend on transferring the approach to high-throughput tandem mass spectrometry platforms. The use of computational data analysis in conjunction with urine steroid metabolite profiling, that is, steroid metabolomics, adds accuracy and precision.

AB - PURPOSE OF REVIEW: Adrenal masses are highly prevalent, found in 5% of the population. Differentiation of benign adrenocortical adenoma from adrenocortical carcinoma is currently hampered by the poor specificity and limited evidence base of imaging tests. This review summarizes the results of studies published to date on urine steroid metabolite profiling for distinguishing benign from malignant adrenal masses. RECENT FINDINGS: Three studies have described cohorts of at least 100 patients with adrenal tumors showing significant differences between urinary steroid metabolite excretions according to the nature of the underlying lesion, suggesting significant value of steroid metabolite profiling as a highly accurate diagnostic test. SUMMARY: Steroid profiling is emerging as a powerful novel diagnostic tool with a significant potential for improving the management for patients with adrenal tumors. Although the current studies use gas chromatography–mass spectrometry for proof of concept, widespread use of the method in routine clinical care will depend on transferring the approach to high-throughput tandem mass spectrometry platforms. The use of computational data analysis in conjunction with urine steroid metabolite profiling, that is, steroid metabolomics, adds accuracy and precision.

UR - http://www.scopus.com/inward/record.url?scp=85013749774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013749774&partnerID=8YFLogxK

U2 - 10.1097/MED.0000000000000333

DO - 10.1097/MED.0000000000000333

M3 - Article

JO - Current Opinion in Endocrinology, Diabetes and Obesity

JF - Current Opinion in Endocrinology, Diabetes and Obesity

SN - 1752-296X

ER -